A treatment planning study of urethra-sparing intensity-modulated proton therapy for localized prostate cancer. (October 2021)

• Record Type: Journal Article
• Authors: Yoshimura, Takaaki; Nishioka, Kentaro; Hashimoto, Takayuki; Seki, Kazuya; Kogame, Shouki; Tanaka, Sodai; Kanehira, Takahiro; Tamura, Masaya; Takao, Seishin; Matsuura, Taeko; Kobashi, Keiji; Kato, Fumi; Aoyama, Hidefumi; Shimizu, Shinichi
• Is Part Of: Physics and imaging in radiation oncology. Volume 20(2021)
• Page Start: 23
• Page End: 29
• Publication Date: 2021-10
• Subjects: Urethra-sparing radiotherapy -- Prostate cancer -- Intensity-modulated proton therapy -- Tumor control probability -- Normal tissue complication probability; Radiotherapy -- Periodicals; Radiation dosimetry -- Periodicals; Cancer -- Imaging -- Periodicals; Oncology -- Periodicals; 615.842
• DOI: 10.1016/j.phro.2021.09.006
• Languages: English
• ISSNs: 2405-6316

Abstract

Highlights: US-IMPT can potentially reduce the risk of genitourinary toxicities. The urethral NTCP value in US-IMPT is significantly lower than in the clinical plan. TCP for CTV did not differ significantly between the clinical and US-IMPT plans. Abstract: Background and Purpose: Urethra-sparing radiation therapy for localized prostate cancer can reduce the risk of radiation-induced genitourinary toxicity by intentionally underdosing the periurethral transitional zone. We aimed to compare the clinical impact of a urethra-sparing intensity-modulated proton therapy (US-IMPT) plan with that of conventional clinical plans without urethral dose reduction. Materials and Methods: This study included 13 patients who had undergone proton beam therapy. The prescribed dose was 63 GyE in 21 fractions for 99% of the clinical target volume. To compare the clinical impact of the US-IMPT plan with that of the conventional clinical plan, tumor control probability (TCP) and normal tissue complication probability (NTCP) were calculated with a generalized equivalent uniform dose-based Lyman–Kutcher model using dose volume histograms. The endpoints of these model parameters for the rectum, bladder, and urethra were fistula, contraction, and urethral stricture, respectively. Results: The mean NTCP value for the urethra in US-IMPT was significantly lower than that in the conventional clinical plan (0.6% vs. 1.2%, p < 0.05). There were no statistically significant differences between the conventional and US-IMPT plans regarding the mean minimum dose for the urethra with a 3-mm margin, TCP value, and NTCP value for the rectum and bladder. Additionally, the target dose coverage of all plans in the robustness analysis was within the clinically acceptable range. Conclusions: Compared with the conventional clinically applied plans, US-IMPT plans have potential clinical advantages and may reduce the risk of genitourinary toxicities, while maintaining the same TCP and NTCP in the rectum and bladder.